Quick-Med and Foster Enter Into
Joint Development Agreement
Companies to Pursue Development of NIMBUS®
Antimicrobial Technology to Catheters to Combat Infections
Gainesville, Florida – March 24, 2009 – Quick-Med Technologies, Inc. announced
today that it has entered into a joint development agreement with Foster Corporation, a
member of PolyMedex Discovery Group, to collaborate in applying Quick-Med’s
proprietary NIMBUS® technology to thermoplastics for catheters and other medical
product applications.
Catheter-associated urinary tract infection is the most common nosocomial (hospital)
infection. Each year, urinary catheters are inserted in more than 5 million patients in U.S.
acute-care hospitals and extended-care facilities and more than 1 million of those patients
acquire a catheter-associated urinary tract infection. When infection occurs, the potential
medical and economic consequences can be tremendous, including increased mortality
and significant additional heath care costs.
“We are excited to team with Foster Corporation to incorporate our NIMBUS technology
in catheters,” said J. Ladd Greeno, CEO of Quick-Med Technologies. “Foster is a
respected leader developing advanced biomedical materials to meet the requirements of
medical device manufacturers. This collaboration will leverage NIMBUS technology to a
next generation of antimicrobial catheters to address growing infection concerns.”
“Our partnership with Quick-Med will enable us to bring innovative, next-generation
antimicrobial technology to meet the needs of both existing and potential customers,”
said Dan Lazas, Foster’s Corporate Vice President, Marketing & Sales. “NIMBUS
technology will continue Foster’s tradition of industry firsts by bringing much needed,
uniquely effective and affordable, innovative antimicrobial protection to thermoplastic
applications for the medical devices market.”
What makes NIMBUS different from other antimicrobial technology are its permanent
bond and its ability to be effective even in the presence of large amounts of serum and
body fluids. The active agent is permanently bonded to the substrate, keeping the biocide
from depletion, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. Being bound to the substrate keeps the antimicrobial at full
strength; test results show that even in 90% serum, NIMBUS continues to kill microbes
outperforming other antimicrobials.
When the development is complete and FDA clearance received, management believes
NIMBUS will bring safe, highly effective, and extraordinarily affordable antimicrobial
protection to the $12 billion global catheter market which is projected to continue rapid
growth for the next several years primarily due to the aging population.
About NIMBUS®
NIMBUS is a next-generation wound care technology that is non-toxic, long-lasting and
not blocked by organics such as blood, urine and perspiration. According to Gregory
Schultz, Professor, Institute for Wound Research at the University of Florida and Past
President of the Wound Healing Society, “NIMBUS poses no danger of bacteria
developing resistance, or of releasing toxic material. It is a novel technology: bonded and
effective even in high concentrations of body fluids.”
About Foster Corporation.
For nearly 20 years, Foster Corporation has been at the forefront of developing and
manufacturing state-of-the-art material solutions based on extremely precise polymer
technologies, with a special focus on serving the medical, pharmaceutical delivery, and
bio-technology sectors worldwide. In February 2009, Foster Corporation and Putnam
Plastics Group merged to form PolyMedex Discovery Group. For more information, see:
www.fostercorporation.com.
|
